|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Novartis
|
|
gptkbp:activities
|
tyrosine kinase inhibitor
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:imatinib_mesylate
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
targeted therapy
Phase I
|
|
gptkbp:contraindication
|
severe liver disease
hypersensitivity to imatinib
|
|
gptkbp:developed_by
|
gptkb:Novartis
|
|
gptkbp:discovered_by
|
gptkb:Dr._Nicholas_Lydon
|
|
gptkbp:dosage_form
|
oral tablet
|
|
gptkbp:effective_date
|
gptkb:2001
|
|
gptkbp:government_type
|
New Drug Application
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gleevec
|
|
gptkbp:indication
|
gptkb:Philadelphia_chromosome-positive_leukemia
gptkb:dermatofibrosarcoma_protuberans
gptkb:myelodysplastic_syndromes
|
|
gptkbp:ingredients
|
gptkb:imatinib
C22 H26 N6 O2 S
|
|
gptkbp:interacts_with
|
gptkb:warfarin
certain antibiotics
certain antifungals
certain anticonvulsants
|
|
gptkbp:invention
|
gptkb:Novartis_AG
gptkb:2015
|
|
gptkbp:is_available_on
|
generic version
|
|
gptkbp:is_used_for
|
gptkb:chronic_myeloid_leukemia
gptkb:gastrointestinal_stromal_tumors
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Gleevec
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:name
|
Essential Medicines List
|
|
gptkbp:operational_status
|
approved
|
|
gptkbp:previous_name
|
gptkb:imatinib
|
|
gptkbp:research_areas
|
molecular biology
oncology
hematology
pharmacology
|
|
gptkbp:safety_features
|
Category D
|
|
gptkbp:shelf_life
|
3 years
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
edema
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:traded_on
|
gptkb:Gleevec
|
|
gptkbp:weight
|
493.6 g/mol
|
|
gptkbp:year_created
|
gptkb:1996
|